TRAVERE THERAPEUTICS, INC. Available-for-sale Securities, Amortized Cost Basis
TRAVERE THERAPEUTICS, INC. (TVTX) had Available-for-sale Securities, Amortized Cost Basis of $204.20 million as of 2018-03-31, per its 10-Q filed 2018-07-06.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-07-06
- 2018-03-31: Available-for-sale Securities, Amortized Cost Basis $204.20M.
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $201.96M.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $205.17M.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $207.09M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2018-03-31 | $204.20M 10-Q · filed 2018-07-06 |
| 2017-12-31 | $201.96M 10-K · filed 2018-07-06 |
| 2017-09-30 | $205.17M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $207.09M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $206.69M 10-Q · filed 2017-05-05 |
| 2016-12-31 | $215.41M 10-K · filed 2018-07-06 |
| 2016-09-30 | $250.65M 10-Q · filed 2016-11-04 |
| 2016-06-30 | $200.30M 10-Q · filed 2016-08-05 |
| 2016-03-31 | $199.18M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $192.44M 10-K · filed 2017-03-01 |
| 2015-09-30 | $94.79M 10-Q · filed 2015-11-06 |
| 2014-12-31 | $5.16M 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |